PAS-24-058: Advancing Hearing and Balance Research Using Auditory and Vestibular Organoids (R01-Clinical Trial Not Allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2023.
National Institutes of Health offered grants of up to $499,999 to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on May 7, 2024.
From the official notice on Grants.gov, last changed October 25, 2023. Checked November 7, 2026.
- Award ceiling$499,999
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR01
- Clinical trialsNot allowed
- Funded byNIDCD
- Median yearly award$781,703
- Typical project length5 years
- R01, Research Project Grant. NIH's standard grant for a defined research project led by a named investigator, usually for up to five years. Other open R01 notices.
Projects funded under PAS-24-058 were run by National Institute on Deafness and Other Communication Disorders (NIDCD, 2 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read PAS-24-058 in the NIH Guide.
Key dates
| Posted | October 25, 2023 |
|---|---|
| Deadline | May 7, 2024 |
| Archived by Grants.gov | June 12, 2024 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Is this a realistic fit?
- Projects NIH funded under this notice had a median yearly award of $781,703; it allows up to $499,999 per award.
- Most of the program's money (77% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The purpose of this NIDCD initiative is to encourage research in the development, characterization, and reproducibility/reliability of human auditory and vestibular organoids. Applications investigating animal organoids are allowable but only if accompanying comparative or other integrated companion studies with human organoids. Singular animal organoid studies alone are not responsive to this funding opportunity. This funding opportunity encourages innovative, reproducible, and novel methodologies and technologies that will drive the reproducibility and holistic longevity of hearing/balance sensory organoids as model systems. The development of novel tools to deliver genes, proteins, molecules, and synthetics that might lead to the successful expansion and longer-term survivability of organoid populations in a stable, reliable, and reproducible manner is highly encouraged. Subsequent characterization of the organoid platforms must be shown to mimic and recapitulate the native correlative biological function. Applications that provide approaches that remove current barriers and lessen challenges to improve current reproducibility and stability are highly encouraged. Applications that have breakthrough approaches and technologies using human auditory/vestibular organoids are highly encouraged.
Funded under PAS-24-058 so far
NIH funded 2 projects under PAS-24-058 in fiscal 2025 to 2026, at 2 institutions. The median yearly award was $781,703.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Sensory Development in Human Cochlear Organoids | Indiana University Indianapolis | 2026 | $781,703 |
| Development of human inner ear organoid platforms for human auditory/vestibular disorders | University of Miami School of Medicine | 2025 | $767,494 |
Who has won Research Related to Deafness and Communication Disorders grants before
From fiscal 2021 to 2025, Research Related to Deafness and Communication Disorders (93.173) awarded $2.1 billion across 2,231 grant awards, an average of $925,005 per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Johns Hopkins University | Maryland | 73 | $82.4 million |
| Massachusetts Eye and Ear Infirmary | Massachusetts | 41 | $78.9 million |
| The University of Iowa | Iowa | 28 | $53.4 million |
| The Leland Stanford Junior University | California | 39 | $46.2 million |
| University of Wisconsin System | Wisconsin | 56 | $45.0 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is PAS-24-058 still open?
No. It closed on May 7, 2024.
Who can apply for Advancing Hearing and Balance Research Using Auditory and Vestibular Organoids (R01-Clinical Trial Not Allowed)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Advancing Hearing and Balance Research Using Auditory and Vestibular Organoids (R01-Clinical Trial Not Allowed)?
Closed May 7, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $499,999 each.
Who has been funded under PAS-24-058?
NIH RePORTER lists 2 projects funded under PAS-24-058 in fiscal 2025 to 2026, at 2 institutions. The most were at Indiana University Indianapolis, University of Miami School of Medicine.
Who has won Research Related to Deafness and Communication Disorders grants before?
The largest recipients over five fiscal years were The Johns Hopkins University, Massachusetts Eye and Ear Infirmary, The University of Iowa. The program made 2,231 awards worth $2.1 billion in that time.
Similar open grants
- NCCIH Natural Product Mid Phase Clinical Trial (R01 Clinical Trial Required)
- NCCIH Multi-Site Feasibility Clinical Trials of Mind and Body Interventions (R01 Clinical Trial Required)
- Investigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth (R01 Clinical Trial Required)
- Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional)
- Competing Revisions to Existing NIH Single Project Research Grants and Cooperative Agreements (Clinical Trial Optional)
- Interventions to expand cancer screening and preventive services to ADVANCE health in populations that experience health disparities (R01, Clinical Trial Required)